Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Zoetis Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.08 (market cap $1.02B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 29.6× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and Zoetis Inc pays a 2.9% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Zoetis Inc for 70 Days on average.
| GSG | ZTS | |
|---|---|---|
Market Cap | $1.02B | $30.20B |
Volume | 1,256,221 | 6,175,327 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $147.53 |
52-Week Low | $22.45 | $69.09 |
Typical Hold Time | 40 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.08, up 1.23% with neutral technical signals. The company reported strong 2024 results with $51.25M revenue and $69.99M net income, though cash flow turned negative at -$932.80K. Assets remain robust at $968.15M with minimal debt, while recent news highlights commodity market volatility and energy sector exposure as key drivers.
Outlook remains cautious due to commodity price sensitivity and geopolitical risks, though strong profitability and clean balance sheet provide stability. Analyst sentiment is mixed with neutral ratings prevailing, suggesting limited near-term catalysts beyond broader commodity trends.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
